Skip to main content
Equibles
CPHI logo

CPHI · China Pharma Holdings, Inc. · Metrics

Track CPHI — free

Use CPHI with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CPHI.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.57 +0.04 (+7.53%) At close · Nov 6
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“As of June 30, 2026, the Company had cash and cash equivalents of $0.3 million and an accumulated deficit of $49.8 million, and the Company's current liabilities exceeded current assets by $5.7 million. In addition, the Company incurred net losses of $2.6 million and had cash outflows from operating activities of $0.08 million for the six months ended June 30, 2026.”
View the 10-Q filed Aug 14, 2026
Market Cap
$22.80M
Shares
43.02M
Volume · Nov 6 41.45K Avg daily vol (3M) 1.81M

CPHI metrics

69 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.57
Market cap
$22.80M

Price action

23 metrics
Price change (1W)
-18.5%
Price change (30D)
-37.6%
Price change (3M)
-56.2%
Price change (6M)
+0.0%
Price change (YTD)
-56.2%
Price change (1Y)
-64.7%
Trailing year
Price change (5Y)
—
52-week high
$8.10
52-week low
$0.52
Change from 52-week high
-93.5%
Change from 52-week low
+1.9%
Annualized volatility
811.3%
Annualized volatility (3M)
95.3%
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
4.9
RSI (14D)
33.0
Price vs SMA 50
-27.3%
Price vs SMA 200
-35.3%
Avg volume (3M)
1.82M
Relative volume
0.1
Average dollar volume
$1.63M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
43.02M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
6.7×
reciprocal yield 15.0%
EV / EBITDA
—
EV / EBIT
—
P / sales
5.8×
reciprocal yield 17.2%
P / book
0.6
reciprocal yield 158.7%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-19.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
5.6×
reciprocal yield 17.8%
EV / revenue historical average (5Y)
3.9×
reciprocal yield 25.4%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
11.8%
Operating margin
-111.8%
Trailing 12 months
Net margin
-114.3%
Gross profit (TTM)
$460,174
Operating profit (TTM)
−$4.38M
Net income (TTM)
−$4.47M
Trailing 12 months
Diluted EPS (TTM)
$-0.42
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$4.12

Growth

11 metrics
Revenue growth YoY
-7.5%
Year over year
Net income growth YoY
—
Revenue (TTM)
$3.91M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+1,156.0%
Year over year · more shares
Revenue CAGR (3Y)
-20.0%
Revenue CAGR (5Y)
-17.5%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-12.4%
Return on assets
-10.0%
Debt / equity
0.1
Current ratio
0.3
EBITDA (TTM)
−$1.44M
Free cash flow (TTM)
—
Quick ratio
0.1
Interest coverage
-136.3
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$3.30M
Latest balance sheet
Cash & equivalents
$304,874
Total assets
$44.71M
Total debt
$3.60M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$140,490
Capital expenditures (TTM)
—
R&D (TTM)
$333,259
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
8.5%
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
8
13F filer change QoQ
+2
Institutional ownership
0.5%
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
0.3%
Active holders' share change QoQ
+690.9%
Holder tenure
1.9
Price vs estimated holder cost
-13.5%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
0.5%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
43 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1106644 CUSIP 16941T401 13F (30d) 3 filings 3 filers Visit website